公开(公告)号：US20240117068A1

公开(公告)日：2024-04-11

申请号：US18538242

申请日：2023-12-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Meike HUTT ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER ,  Martin HOFMANN ,  Gabriele PSZOLLA ,  Sara YOUSEF ,  Claudia WAGNER ,  Frank SCHWOEBEL ,  Heiko SCHUSTER

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/725

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/7051 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20230357428A1

公开(公告)日：2023-11-09

申请号：US18301545

申请日：2023-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  C07K16/2809 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20230091330A1

公开(公告)日：2023-03-23

申请号：US17934303

申请日：2022-09-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20230065320A1

公开(公告)日：2023-03-02

申请号：US17937165

申请日：2022-09-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230057987A1

公开(公告)日：2023-02-23

申请号：US17874711

申请日：2022-07-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

公开(公告)号：US20210380659A1

公开(公告)日：2021-12-09

申请号：US17354555

申请日：2021-06-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Jens FRITSCHE ,  Claudia WAGNER ,  Leonie ALTEN ,  Franziska HOFFGAARD ,  Mathias FERBER

IPC: C07K14/725 ,  C12N15/09 ,  A61K35/17 ,  C12N5/0783

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

公开(公告)号：US20210101975A1

公开(公告)日：2021-04-08

申请号：US17125135

申请日：2020-12-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Dominik MAURER ,  Meike HUTT ,  Claudia WAGNER ,  Leonie ALTEN

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/18 ,  C07K14/78 ,  A61P35/00 ,  C07K14/775 ,  C12N5/0783 ,  C12N15/62

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20210024635A1

公开(公告)日：2021-01-28

申请号：US17069136

申请日：2020-10-13

Applicant: Immatics Biotechnologies GmbH ,  Morphosys AG

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Dominik MAURER ,  Claudia WAGNER ,  Klaus Felix HARTLEPP ,  Alexandra KRAUS

IPC: C07K16/28 ,  C07K16/18 ,  G01N33/53 ,  C07K14/47 ,  G01N33/68

Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.

公开(公告)号：US20190388531A1

公开(公告)日：2019-12-26

申请号：US16563151

申请日：2019-09-06

Applicant: Immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/74 ,  C07K14/47 ,  C07K16/18

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190321478A1

公开(公告)日：2019-10-24

申请号：US16403003

申请日：2019-05-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: A61K47/55 ,  C07K14/47 ,  A61K39/00 ,  C12N5/00 ,  A61P35/00 ,  C12N15/85 ,  C07K14/725 ,  A61K35/17 ,  A61K47/64 ,  C07K14/705 ,  A61K38/17 ,  C07K14/73 ,  A61K38/00

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.